John Finney, Chairman John D. Finney is Chairman of the Board of Directors. Along with his brother, Michael J. Finney, Ph.D., Mr. Finney founded and grew MJ Research and MJ Bioworks, two businesses were the premier providers of instrumentation and reagents for genome analysis. Mr. Finney received his A.B. in Economics from Harvard University. He continues to serve as Chairman of Gcorp, Inc. and of GeneWorks Pty Ltd.
Michael Finney, Ph.D., Investor Dr. Finney is an investor based in San Francisco. He was a founder of MJ Research, and is currently an investor in over a dozen privately-held companies in biotechnology, alternative energy, and allied areas. He is a director of the privately held companies Vaxart, Wavemark, Innerscope, and Sage Science, and past director of Mission Motors and Pharmasecure; he is also Chief Executive Officer of Vaxart. Dr. Finney received his Ph.D. in Biology from the Massachusetts Institute of Technology, and was a Postdoctoral Fellow at Harvard Medical School/Massachusetts General Hospital. He holds seven U.S. patents.
Nathan D. Lakey, MBA, President and Chief Executive Officer Mr. Lakey is President and Chief Executive Officer and a member of the Board of Directors. Regionally, Mr. Lakey was awarded the top 40 under 40 award (2004 St. Louis), presented the governor's top technology award (2005 Missouri), and he currently serves on the Patient Care Committee of the Board of Missouri Baptist Hospital. Mr. Lakey was founding principal of Orion and has served as President and Chief Executive Officer since June 2000. Mr. Lakey has more than 20 years of experience in genomics. Prior to the founding of Orion Genomics, he was Director of DNA Sequencing at Millennium Pharmaceuticals, Inc., in Cambridge, Massachusetts (1994-98), where he built and operated Millennium's DBA sequencing platform, and helped form three strategic business units - Millennium Predictive Medicine, Millennium Biotherapeutics and Cereon Inc. Before joining Millennium, Mr. Lakey held various positions with Molecular Dynamics (Sunnyvale, CA), Ambion Inc (Austin TX) and Harvard Medical School, Department of Genetics, in George Church's laboratory. Mr. Lakey received a B.A. in Biochemistry from the University of Texas (Austin), and an MBA from Washington University Olin School of Business (St. Louis) where he received the C. William Emory Executive MBA Award. Mr. Lakey holds 3 issued US patents and multiple pending applications.
W. Richard McCombie, Ph.D., Professor Cold Spring Harbor Laboratory Dr. McCombie is a member of the Board of Directors and a scientific co-founder of the Company. He is a Professor at Cold Spring Harbor Laboratory, Cold Spring Harbor, New York. Dr. McCombie received his B.A. in Biology from Wabash College, his Ph.D. in Cell and Molecular Biology from the University of Michigan, and was a Postdoctoral Fellow in the Microbiology Department of the University of Texas (Austin). He worked in the area of yeast gene expression at Phillips Petroleum, and was a Senior Staff Fellow at the National Institutes of Health, where he was the leader of one of the first groups to carry out large-scale automated sequencing of genomic DNA and helped to organize the first large-scale EST sequencing project. He has been on the faculty at Cold Spring Harbor Laboratory since 1992.
John D. McPherson, Ph.D. Orion Genomics Cancer Genomics Director Cancer Genomics Director and Senior Principal Investigator Ontario Institute for Cancer Research Dr. McPherson is a member of the Board of Directors, and is a scientific co-founder of the Company. He is currently the Cancer Genomics Director and Senior Principal Investigator, Ontario Institute for Cancer Research, and Professor, Department of Medical Biophysics, University of Toronto, Toronto, Canada. He is focusing on genomic characterization of tumors for gene target and biomarker discovery for improved detection, diagnosis and treatment potential. His laboratory has major efforts in pancreatic and prostate cancer as well as integrating high-throughput sequencing technologies into the clinical decision tree for therapeutic intervention. Previously, he was Associate Professor of Molecular and Human Genetics at Baylor College of Medicine and faculty member of the Human Genome Sequencing Center (2003-2007) where his research focused on utilizing high-throughput genomic resources to study human disease and functional genomics. Dr. McPherson's prior appointments were Associate Professor of Genetics and Co-Director of the Genome Sequencing Center at Washington University School of Medicine, St. Louis, Missouri (1995-2003) and Assistant Professor of Biological Chemistry and Co-Director of the Human Genome Research Center at the University of California at Irvine (1994-1995). Dr. McPherson is an expert in genomics and played a lead role in the generation of the human and mouse physical maps as part of the Human Genome Project. Dr. McPherson received his B.S. and Ph.D. in Biochemistry from Queen's University (Ontario) and was a Postdoctoral Fellow in the Biochemistry Department at the University of California (Irvine).
Richard K. Wilson, Ph.D., Professor of Genetics and Molecular Microbiology Washington University School of Medicine Director, Genome Sequencing Center Dr. Wilson is a member of the Board of Directors and a scientific co-founder of the Company. He served as Interim CEO and Chairman of the Board of Directors during Orion's start-up phase. Dr. Wilson is Professor of Genetics and Professor of Molecular Microbiology at Washington University in St. Louis and Director of The Genome Institute. He is an expert in molecular genetics and large-scale DNA sequence analysis. His laboratory at the Washington University School of Medicine has sequenced and analyzed billions of bases of DNA from the genomes of bacteria, yeast, roundworms, plants, vertebrates, primates and humans. He and his colleagues at The Genome Institute sequenced the first animal genome - that of the roundworm Caenorhabditis elegans - and contributed substantially to the sequencing and analysis of the human genome. More recently, his laboratory was the first to sequence the genome of a cancer patient and discover genetic signatures relevant to the pathogenesis of the disease. Building upon this achievement, Dr. Wilson's laboratory has sequenced the genomes of several hundred patients in an effort to discover clues that will facilitate more effective diagnosis and treatment of cancer and other human diseases. This includes participation in the Pediatric Cancer Genome Project and The Cancer Genome Atlas. In addition to his position at The Genome Institute, Dr. Wilson is also a Research Member at the Siteman Cancer Center, and a member of their Senior Leadership Committee. He received his B.A. degree from Miami University in Ohio in 1981, his Ph.D. from the University of Oklahoma in 1986 and was a Research Fellow in the Division of Biology at the California Institute of Technology (1986 - 1990). In 2008, Dr. Wilson was elected as a Fellow of the American Association for the Advancement of Science (2008). In 2011, he received the Distinguished Achievement Award from Miami University, and the Distinguished Alumnus Award from the University of Oklahoma College of Arts and Sciences.